Targets › CD14
1 program from 1 company in 3 trials: 2 Phase 1, 1 Phase 2; Cardiovascular, Respiratory; next expected readout Mar 2029.
Coreceptor for bacterial lipopolysaccharide. In concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4 complex, thereby mediating the innate immune response to bacterial lipopolysaccharide (LPS). (UniProt, P08571)
Open in Phaseline: the race on CD14, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Implicit Bioscience | Ic14 (IC14) Monocyte differentiation antigen CD14 inhibitor | CD14 | Phase 2 | Acute Respiratory Distress Syndrome; Acute Decompensated Heart Failure; STEMI | Mar 2029 |
Acute Respiratory Distress Syndrome (1) Acute Decompensated Heart Failure (1) STEMI (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.